Key takeaways for New York
- • Insulin resistance is not a labeled FDA indication for any GLP-1.
- • Improvements typically substantial (30-50% HOMA-IR reduction).
- • Treat via parent diagnosis (obesity, PCOS, T2D, prediabetes).
- • New York Medicaid coverage rules apply for Insulin Resistance patients in New York — see Medicaid section below.
- • 13 GLP-1 telehealth providers available nationwide.
Why GLP-1 medications for Insulin Resistance
There is no FDA indication for insulin resistance as a standalone diagnosis — it is a physiological state, not a labeled disease. GLP-1 therapy improves insulin sensitivity through weight loss, slowed gastric emptying, glucagon suppression, and beta-cell function preservation. Evidence grade: B. Patients with insulin resistance are typically treated via comorbid diagnoses (obesity, prediabetes, PCOS, T2D). HOMA-IR scores typically improve 30-50% with sustained semaglutide or tirzepatide therapy.
New York-specific context
New York has telehealth access concentrated in New York City, Buffalo, Yonkers metros, with additional reach to Rochester and Syracuse. NewYork-Presbyterian, NYU Langone, Mount Sinai, Northwell Health is the largest in-state academic medical center for endocrine + obesity-medicine specialty consults. The state health authority publishes prescribing + coverage updates at www.health.ny.gov.
New Yorktelehealth & pricing rules
- • New York requires a live video consultation before a GLP-1 prescription.
- • New York allows new-patient telehealth prescribing without a prior in-person visit.
- • Typical cash GLP-1 price in New York: ~$312/mo (compounded options often lower, brand higher).
State telehealth statutes change — verify current rules with your provider before booking.